Sol-Gel Technologies SLGL
NASDAQ SLGL
$69.96 -0.14 (-0.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

Sol-Gel Technologies (SLGL) Receivables - Net (2019 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Receivables - Net of $2.0 million for Q4 2025, down 45.26% year-over-year from $3.6 million in Q4 2024, and down 80.4% quarter-over-quarter from $10.0 million in Q2 2025.

Analysis

Sol-Gel Technologies (SLGL) Receivables - Net (2019 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Receivables - Net for 7 consecutive years, with $2.0 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Receivables - Net fell 45.26% year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $2.0 million (down 45.26% YoY), while the FY2025 annual figure was $2.0 million, down 45.26% from the prior year.
  • Receivables - Net retreated to $2.0 million in Q4 2025 per SLGL's latest filing, from $10.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $13.1 million in Q4 2021 and bottomed at $377000.0 in Q4 2023.
  • Historically, Receivables - Net has averaged $5.6 million across 5 years, with a median of $5.8 million in 2023.
  • Annual changes were most pronounced in 2022 — Receivables - Net soared 1268.27% — and 2023, when it slumped 95.2%.
  • Sol-Gel Technologies' Receivables - Net stood at $13.1 million in 2021, then tumbled by 39.85% to $7.9 million in 2022, then plunged by 95.2% to $377000.0 in 2023, then jumped by 853.58% to $3.6 million in 2024, then slumped by 45.26% to $2.0 million in 2025.
  • Business Quant data shows SLGL's Receivables - Net at $2.0 million in Q4 2025, $10.0 million in Q2 2025, and $3.6 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Sol-Gel Technologies 194.01 Mn 146.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 713,000.00
Mar 31, 2026 1.07 Mn
Dec 31, 2025 1.97 Mn
Sep 30, 2025 9.85 Mn
Jun 30, 2025 10.04 Mn
Mar 31, 2025 3.88 Mn
Dec 31, 2024 3.60 Mn
Sep 30, 2024 7.02 Mn
Jun 30, 2024 6.06 Mn
Mar 31, 2024 869,000.00
Dec 31, 2023 377,000.00
Jun 30, 2023 2.21 Mn
Mar 31, 2023 5.81 Mn
Dec 31, 2022 7.86 Mn
Sep 30, 2022 10.78 Mn
Jun 30, 2022 10.18 Mn
Mar 31, 2022 9.66 Mn
Dec 31, 2021 7.40 Mn
Sep 30, 2021 1.39 Mn
Jun 30, 2021 956,000.00